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GOALS-OF-CARE & END-OF-LIFE QUALITY IN RELAPSED HIGH-RISK
LEUKEMIA: SILENT CONVERSATIONS

An Abstract of the Scholarly Project by
Lacy Jo Graham
BACKGROUND: The distorted association of “end of life (EOL)” with “goals of care
(GOC)” has “silenced” crucial goals discussions in patients with relapsed high-risk
leukemia, which raises concerns for the provision of care that is inconsistent with
patient’s values and preferences (Desharnais et al., 2007; Epstein et al., 2016; Gilligan et
al., 2017; Mack et al., 2010; Piggott et al., 2019; Weeks et al., 2012).
AIM: The two main goals of this study were to quantify hematologists rate of
participation in a GOC pathway initiative during two separate months, then explore their
definition and barriers to having/documenting GOC discussions.
DESIGN: Mixed-methods, explanatory sequential design (follow-up explanations
variant).
SAMPLE: Quan: Hematology inpatient admissions during the months of October 2020
and January 2021. Qual: Eighteen leukemia hematologists from one dedicated cancer in
the United States.
RESULTS: During the two months, an average of 36% of admissions met criteria for
GOC pathway initiation, 19% of those had an appropriate initiation order, of which
15.5% had a properly documented and billed GOC discussion. Nine hematologists
responded to the SurveyMonkey with two questions. All nine included clinical situation
and communication in their definition/components of GOC discussions. Time required
and prognostic uncertainty were the two most mentioned barriers.
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CHAPTER I
INTRODUCTION
The consistent provision of high-quality healthcare by Advanced Practice
Providers (APP) has been clearly established and widely recognized in the literature.
Initially utilized only in rural, underserved primary care settings, value recognition and
good outcomes have prompted mass expansion of scope and specialty role opportunity
for these providers, one such specialty being hematology. Collectively, APP’s exhibit a
strong drive to advocate for, influence, and affect high-quality health care through
leadership, evidence-based practice implementation, and quality improvement projects
(Sarzynski & Barry, 2019). A southern California dedicated cancer center and research
hospital that specializes in hematological malignancies has adopted an inpatient work
model that requires the APP to routinely work very closely with and collaborate with
many different hematologists. A rotating 14-day inpatient rounding schedule requires
each of 35 hematologists to round only 4-6 weeks/year. Eighteen of the 33 hematologists
specialize in leukemia, myelodysplastic syndrome, or other blood disorder and rotate
through the four leukemia inpatient services. There are often months between inpatient
obligations, and for this reason, these physicians rely heavily on APP’s to guide them
through frequent process and policy changes, quality improvement initiatives, and
provide a component of care continuity. The nature of this relationship places the APP in
1

a role of leadership with significant opportunity to observe, analyze, and influence the
practice habits of physicians. This role also provides opportunity for the APP to identify
and address barriers, in order to establish, hone, and strengthen collaborative multidisciplinary relationships.
Clinical Problem/Issue
In 1997 The Institute of Medicine (IOM) published a report titled “Approaching
Death: Improving Care at the End of life” that focused on the dying and deaths of adults
in America. A pediatric version, “When Children Die: Improving Palliative and End-ofLife Care for Children and their Families” was published in 2003. In 1999 the IOM
released Ensuring Quality Care, emphasizing that quality care measurement and
improvement should not only focus on cancer detection and treatment, but should span
the entire disease trajectory, including EOL care (as cited in Odejide, 2016). By 2013,
impressively, many of the goals articulated in the 1997 report had been achieved,
including creation of palliative medicine specialty status, increased access to opioids for
patients with pain, and the widespread adoption of hospital palliative care teams. And yet,
both in research and in the everyday experience of patients, family members, and
clinicians, huge gaps remained in the quality of care for the most vulnerable patients. In
response, the IOM assembled a diverse panel that, in 2014, issued Dying in America:
Improving Quality and Honoring Individual Preferences Near the End-of-Life. The
consensus study report organizes findings across five domains: care delivery, clinicianpatient communication and advance care planning, professional education, policies and
payment systems, and public education and engagement. It was discovered that although
access to specialist palliative care had grown dramatically over the previous 15 to 20

2

years, the experience for most patients and families still fell short of what ought to be the
standard. The report also notes that patients nearing the EOL ought to receive treatments
that match their preferences and goals for care. The last few months of an individual’s
life is often characterized by frequent hospital admissions, intensive care stays, and
burdensome transitions across care settings (Tulsky, 2015). A large proportion of deaths
continue to occur in hospitals and promulgate poor quality EOL care and unsustainable
costs for the health care system. The 2014 report provides recommendations for creating
transformational change in the models of EOL care delivery, clinician-patient
communication, and advance care planning (as cited in Meghani & Hinds, 2015).
Quality End-of-Life Care in Hematology
The clinical course of hematology-oncology patients differs from patients with
solid malignancies as these patients are more likely to be admitted and receive life
sustaining measures near EOL. In a survey conducted among hematologist-oncologists,
EOL indicators validated for medical oncology patients and considered significant for
hematology-oncology patients, included not being admitted to intensive care, not being
intubated or receiving cardiopulmonary resuscitation (CPR) within 30 days of death, not
receiving chemotherapy within 14 days or a blood transfusion within 7 days of death, and
dying outside of an acute care unit (Odejide et al, 2016). The most recent published
findings of Korsos et al. (2019) demonstrates that having level of intervention
discussions, palliative care consults and physician/patient established goals of treatment
may improve EOL quality for patients with hematologic malignancies.
Low-Quality End-of-Life Care
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Patients with hematologic malignancies often receive aggressive care at the EOL,
leading to lower quality of life. While the use of billed palliative care services among
Medicare beneficiaries with hematologic malignancies has steeply increased in recent
years, most encounters still occur within days of death in the inpatient setting (Rao, et al,
2019). Aggressive EOL care in patients with advanced-stage cancer is increasing despite
growing concerns that this reflects poor-quality care (Wright et al, 2016). Furthermore,
studies have found that, regardless of illness, at least 13% of the time, the EOL care
provided is inconsistent with the patients’ goals-of-care (GOC) and causes psychosocial
and financial burden to the family (Khandelwal et al, 2017). Data regarding this
phenomenon in hematology specifically, is lacking.
Goals-of-Care, Palliative Medicine, and End-of-Life Care
The GOC conversations may be defined as discussions about prognosis and
treatment options that clarify patients’ values, goals, and priorities. GOC conversations
do not routinely occur among patients with advanced cancer, and when they do, it is often
late in the course of the illness (Childers, 2017). Ideally, initial, intermediate, and final
GOC conversations should occur throughout the illness trajectory (Schulman-Green et
al., 2018). EOL discussions should be a component of GOC and should be discussed at
various times throughout the illness. Integrated palliative care is correlated with earlier
EOL discussion and improved quality of life (Mack et al., 2012). National guidelines
(Ferrell et al., 2018) recommend that discussions about EOL care planning happen early
for patients with incurable cancer, but, for various reasons, these discussions are still
occurring within days of death. Hematologists have specific barriers that interfere with
timely EOL discussions, and integration of palliative care specialists may enable earlier
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EOL discussions in patients with hematologic malignancies. Early EOL discussions are
prospectively associated with less aggressive care and greater use of hospice at EOL.
GOC conversations should promote informed shared decision making by presenting
accurate prognostic information and treatment options to patients and their families and
ensure patient/physician concordance of goals is achieved (Mack et al., 2012). Patients
with incurable cancer, and those participating in Phase I trials often have misconceptions
regarding the goals of their treatment regimens (Enzinger et al., 2014). One study found
that 69% of patients with lung cancer and 81% of those with colorectal cancer did not
report understanding that chemotherapy was not at all likely to cure their cancer (Weeks
et al., 2012).
Hematologists are Different
Historically, hematologists collectively possess certain personality traits, thought
processes and practice paradigms that result in very specific barriers to having GOC and
EOL discussions. Several authors have tried to understand the reason why integrating
palliative care into hematology is so difficult. Hematologists describe particular issues,
such as the difficulty for individual prognostication due to the chemo-sensitivity of
hematological malignancies, and the possibility of allogeneic stem cell transplantation
that allow ongoing therapeutic goals of curable or long-term survival. In contrast, acute
complications are frequent, unpredictable and change the prognosis rapidly (Prod’homme
et al., 2018). Often the acute complications may contribute to death before the possible
involvement of a palliative care team. Furthermore, long relationships that develop
between patients and their hematologists and the negative representation of palliative care
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as addressed to dying patients also contributes barriers for referral (Prod’homme et al.,
2018).
Having, Documenting, and Billing for Advance Care Planning
The barriers to Advance Care Planning in hematologic malignancies exist on
many levels, are vast, ongoing, and will require system tools, policies, multidisciplinary
collaboration, and APP leadership to address these quality shortcomings. Unfortunately,
as with most issues in healthcare, this is a complex problem with another problem
uncovered in every solution. Protocols and policies often are met with opposition and
slow adoption in a Southern California Cancer research hospital, and despite protocol
initiation, significant education, and leadership backing on this issue, compliance remains
low. Occurrence of GOC and EOL conversations are lacking, documentation of these
conversations remains low, and Intensive Care Unit (ICU) admission in the last 30 days
of life remains higher than at similar facilities, despite efforts to address this issue.
Significance
Patient and Family
Identification of poor prognosis patients, initiating GOC conversations, and
ensuring proper documentation of these conversations can reduce misaligned treatment
and patient/family suffering. Earlier GOC discussions will better prepare the patients for
the day they are “in a different place” in their illness trajectory. Discussing EOL when
they are not near the EOL allows time to explore their goals and share them with their
family. Discussing health care wishes with a designated speaker reduces the stress on
family when making decisions for the patient at the EOL. Physical and psychological
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symptom burden may be reduced with earlier palliative care collaboration, and overall
quality at the EOL will improve for patients (Back et al., 2014).
Advanced Practice Nurse/Advanced Practice Provider (APP)
The emotional burden is globally present in APPs who work in inpatient
hematology, though it varies in etiology and intensity for many reasons. The barriers to
EOL discussions that exist in hematologists are different than those existing in APPs.
Therefore, APP's often experience emotional distress after witnessing incomplete
prognostic conversations and excessive offering of treatment that will yield little to no
benefit. APP’s see recommendations being made without discussing or considering
patient goals and are painfully aware of the suffering the patient will certainly endure.
The level of sharing obtained during the more personable conversations between patients
and APP’s often uncovers the true misconceptions patients have regarding their
treatment, prognosis, and chance of meaningful recovery, but hospital culture and their
role prevents them from exploring these misconceptions and false hopes. This deeper
emotional knowledge presents an ethical struggle and can lead to burnout, anxiety, and
depression (Bourdeanu, 2020). The unique opportunity the APP has to influence
physician practice and shift paradigms is significant and should be recognized and
utilized to generate and disseminate new research and policies pertinent to the practice.
Specific Aims/Purpose
While the global issue discussed is large and multifaceted, any quality
improvement-research endeavor requires a step-wise approach in which the completion
of each stage will likely reveal another issue to be addressed in future research.
Application of the “Five Why’s” approach (see Figure 1), initially developed by Sakichi
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Toyoda in the 1930’s revealed the focus of this scholarly project: protocol utilization and
compliance/non-compliance, and why. Prior to designing and completing this study,
hospital leadership had placed the researcher on a task force deemed responsible for
reducing ICU admissions within 30 days of death in the Southern California Cancer
Research facility described above. A hospital based GOC pathway pilot program was
created and implemented as a potential solution to the fourth “why,” avoidance of GOC
discussions. The pathway addresses hematologists evasion of GOC conversations by
permitting APP initiation of the pathway process using specific criteria to identify and
refer high-risk/poor-prognosis patients. Once the referral is made, a social worker
administers a patient and caregiver support screen (Appendix A), which evaluates
prognostic understanding. These results are shared with the inpatient team and primary
hematologist in a request for a family meeting.
Shortly after the March 2020 GOC pathway implementation the issue of
documentation/billing became apparent, and the project objectives were updated. Even
when the hematologists were having GOC discussions, they were not documenting them
in a standardized place or way, and were not billing for their time, making it difficult for
other providers to access and update. The objectives of the hospital based GOC pathway
were modified to the following: 1) Augment GOC pathway project by optimizing the
primary hematologists’ ease of execution and level of comfort during GOC discussions.
2) Establish a documentation process that is easily completed and accessed (without
using the search option or “hunting”) by other providers during subsequent encounters. 3)
Discover actual and potential APP contribution to the GOC pathway pilot project. The
Joint Commission National Quality Measures (2018) calls for increased documentation in
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the medical record of GOC. A metric to be measured, and first purpose of the scholarly
project was to evaluate the participation of physicians and APPss in the GOC pathway
process through quantification of patients who met the established “poor-prognosis”
criteria for pathway initiation, patients with appropriate social work referrals to initiate
the pathway, and those with a properly documented GOC discussion in the electronic
medical record during that hospital encounter. A user-friendly Advance Care Planning
(ACP) documentation template was created and rolled out one month prior to this inquiry
into usage. The second purpose was to gain insight into the hematologists self-reported
definition of a GOC discussion, the most important components, and their perceived
barriers. The goal was to collect and synthesize the candid thoughts, opinions, attitudes,
beliefs, practice habits, philosophies, perceptions, and comfort level surrounding GOC
discussions and the proper documentation and billing of these conversations. Five
project research questions were constructed to achieve the two purposes.
Project Questions
1. How many leukemia inpatients met the established GOC pathway criteria for poor
prognosis upon admission during the months of October 2020 and January 2021?
2. How many poor prognosis leukemia inpatients admitted in October 2020 and
January 2021 had appropriate referral for GOC pathway?
3. How many poor prognosis leukemia inpatients admitted in October 2020 and
January 2021 had a properly documented and billed GOC discussion utilizing the
approved template prior to hospital discharge or death?
4. How do the hematologists define “GOC conversation” in one sentence and what
do they consider the most important components?

9

5. What do the hematologists identify as perceived barriers in having/documenting
GOC conversations?
Figure 1
The Five "Whys"
Lower EOL quality in patients with hematologic malignancies-WHY?
Hospital/ICU admissions at
the EOL

Chemotherapy in the last 14
days of life

No CPR or Intubation in the
last 30 days of life

Transfusions at EOL

Patients with hematologic malignancies have higher rates of ICU admission in the last 30 days
of life- WHY?
Lack of goal concordance
Lack of clear goal understanding

Patients often unaware that treatments are
palliative and not curative

Unrealistic expectations of experimental
treatment by both patients and
hematologists

Goal disconcordance, EOL care inconsistent with patient values- WHY?
Hematologists avoid GOC discussions for
many reasons and there is no
standardized documentation process

Assumptions by both patients and
hematologists
Lack of prognostic understanding

Low rates of Palliative and Supportive
Care Medicine in Hematology

Hematologists avoid GOC discussions, no system in place to prompt- WHY?
Creation and initiation of
GOC Pathway program

Unaware of documentation
template
Didn't know they could bill

Fear of ruining hope, culture

Time consgtraints, prognostic
uncertainty, association with
EOL/DNR

GOC pathway participation-DESCRIBE/EXPLAIN WHY or WHY NOT?
Consolidated Framework for
Implementation Research

Attitude, beliefs, perceived barriers,
opinions
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Quantify number of patients who 1) meet
criteria, 2) have pathway initiated, 3)have
properly documented and billed GOC

Definition of Key Terms/Variables
Advance Care Planning (ACP): a process that supports adults at any age or stage of
health in understanding and sharing their personal values, life goals, and preferences
regarding future medical care. The goal of ACP is to help ensure that people receive
medical care that is consistent with their values, goals, and preferences (Sudore et al.,
2017).
Advanced Practice Provider (APP): Physician Assistants and nurses who have met
advanced educational and clinical practice requirements and include Nurse Practitioners
(NPs), clinical nurse specialists, nurse anesthetists, and nurse midwives (American
Nurses Association, n.d.).
Aggressive end-of-life care: ICU admission with or without mechanical ventilation in the
last 30 days of life, CPR administration in the last 30 days of life, death in ICU.
Burnout: A state of mental and physical exhaustion caused by one’s job (Freudenberger,
1974).
Continuity of Care: Idealized in the patient's experience of a “continuous caring
relationship” with an identified health care professional (Guilliford et al., 2006).
Emotional Distress: A highly unpleasant emotional reaction which results from another’s
conduct (Webster, 2020).
End-of-Life Care: Care provided to a person with a terminal condition that has become
advanced, progressive, and/or incurable in the last 30-90 days of life (COH GOC task
force, 2020).
Epic: Electronic Medical Record utilized in Southern California cancer research hospital
for inpatient and outpatient documentation.
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Evidence-Based Practice: The conscientious, explicit and judicious use of current best
evidence in making decisions about the care of the individual patient” is a standard
definition of Evidence-based Practice (EBP). Developed by David Sackett, a pioneer in
EBP, this definition describes integrating individual clinical expertise with the best
available external clinical evidence from systematic research (Agency for Healthcare
Research and Quality, 2020).
Goal Concordance: Care that matches patients’ preferences, enabled by communication
between clinicians and patients or their surrogates (Sanders et al., 2018).
Goals of Care (GOC): Derived based upon the patient’s expressed preferences, values,
needs, concerns and/or desires, may be curative, rehabilitative, life-prolonging, or
comfort focused (The Joint Commission, 2018).
Goals-of-Care Discussion/Conversation: The clinician-led discussion, professional
guidance and support provided to the patient and family intended to result in making
decisions that reflect the goals and values of the patient.
Goals-of-Care Pathway: Pathway protocol created by the GOC task force to reduce ICU
admission in the last 30 days of life that utilizes criteria to identify poor prognosis
patients and initiate GOC conversations and earlier palliative referral (COH Goals-ofCare task force, 2020).
Hematologic Malignancies: Cancers that affect the blood, bone marrow, and lymph
nodes. This classification includes various types of leukemia (acute lymphocytic (ALL),
chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma,
and lymphoma (Hodgkin's and non-Hodgkin's (NHL) (Fowler et al., 2011).
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High-Quality Healthcare: The assessment and provision of effective and safe care,
reflected in a culture of excellence, resulting in the attainment of optimal or desired
health (Allen-Duck et al., 2017).
Life-Sustaining Measures: Interventions aimed to prolong length of life through
mechanical and pharmacological means, Cardio-Pulmonary Resuscitation, endotracheal
intubation, renal replacement therapy, vasopressor blood pressure support (Zhang et al.,
2009).
Palliative and Supportive Care Medicine (PCM, SCM or PSCM): Care given to
improve the quality of life of patients who have a serious or life-threatening disease. The
goal of supportive care is to prevent or treat as early as possible the symptoms of a
disease, side effects caused by treatment of a disease, and psychological, social, and
spiritual problems related to a disease or its treatment (Hui et al., 2015).
Poor-Prognosis Patient: Relapsed or refractory Acute Myeloid and Acute lymphoblastic
leukemia after 1 line of therapy; Lymphoma or Myeloma with disease progression after
at least two prior lines of therapy; exclusions: admission for curative intent treatment (i.e.
allogeneic hematopoietic stem cell transplant or cellular therapy in a relapsed or
refractory patient) (COH GOC task force, 2020).
Prognostication: A prediction of future medical outcomes of a treatment or a disease
course based on medical knowledge (Sinclair, 2007 as cited in Medscape, 2007)
Theoretical Framework
The Consolidated Framework for Implementation Research (CFIR) is a useful
tool for guiding rapid-cycle evaluation of the implementation of practice transformation
initiatives (Keith et al, 2017). Many research-proven interventions fail to translate into
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meaningful change in the healthcare delivery system. Some estimates indicate that up to
two-thirds of organizations’ efforts to implement change, fail (Burnes, 2004). Without
adaptation, interventions usually come to a setting as a poor fit, resisted by individuals
who will be affected by the intervention, and requiring an active process to engage
individuals in order to accomplish implementation. During implementation, it is
important to monitor progress for unanticipated influences (barriers and facilitators) and
progress toward implementation goals (Damschroder et al., 2009).
The CFIR will serve as a roadmap for pathway project evaluation and data
gathered in this study will provide valuable information to fill in existing gaps in
knowledge of the 5 domains of the CFIR. The CFIR comprises five major domains (the
intervention, inner and outer setting, the individuals involved, and the process by which
implementation is accomplished, see Figure 2), each of which will be examined to
evaluate intervention implementation progress as it pertains to the GOC pathway pilot
project.
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Figure 2
Consolidated Framework for Implementation Research 5 Domains

Intervention

Implementation
Process

Inner Setting

Characteristics
Individuals
Involved

Outter Setting

In addition to the CFIR, Rogers (1962) Diffusion of Innovation Theory (see
Figure 3) contributed to the theoretical framework of the project goals and design. The
researcher recognized the potential ability of APP leadership in diffusion of innovation as
a respected opinion leader, change agent, and champion within the institutional social
system. The doctorly prepared APP has both the skill and a unique advantage in leading
change by exercising his/her role as an innovator and early adopter to positively influence
practice change initiatives.
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Figure 3
Diffusion of Innovation Model

Visionaries
and
Inthusiasts

• Innovators
• Early
Adopters

Mainstream
Adopters

• Early
Majority
• Late
Majority

Resisters

• Laggards

Logic Model
A logic model (see Figure 4) assists in brainstorming and planning for the project
and project needs. Mapping resources, activities and outputs provides a platform for
project initiation to be added to as the project develops. Objectives, including short,
medium, and long-term outcome measures (see Figure 5) will guide project evaluation at
various stages and tie the activities to the outcomes.
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Figure 4
Logic Model

Objectives

Resources

Activities

Describe the phenomenon
of hematologist aversion to
GOC discussions

ICU task force

Establish expertise of
process.

Administrative and
physician buy-in

Acquire knowledge and data

Quantitative and qualitative
data

Determine levels of
compliance/non-compliance
with GOC pathway initiation

Explore hematologists
attitudes, beliefs, and
opinions regarding GOC
conversations and pathway

Outputs

Meaningful depiction of
barriers to GOC pathway
Multi-disciplinary
collaboration

Critical analysis

Established process

Recognition and planning
for future initiatives

Personalized interventions
based on qualitative
findings

Figure 5

Quantify appropriate pathway
initiation and completion of MD
documentation/billing in poor
prognosis patients.
Compile the hematologists
personal perceived barriers in
having/documenting GOC
discussions.
Obtain and compile the
hematologists personal
definition of a GOC discussion.

Analyze qualitative data for
patterns and themes specific to
this set of Hematologis.
Interpret and organize findings.
Share the findings with
hematologists, Nurse
Practitioners, and GOC task
force.
Publish findings as scholarly
project.

LONG

Quantify the number of patients
who meet GOC pathway criteria
in 2 seperate months.

MEDIUM

SHORT

Outcomes

Use findings to address specific
concerns and create
educational interventions for
this group of physicians.
Expansion of program to
outpatient setting.

Reduction of ICU admissions in
the last 30 days of life
Enhance and align hematologist
understanding of the GOC
pathway and the intended
outcomes of the project.
Improve goal-concordant care
in high-risk leukemia patients.
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CHAPTER II
REVIEW OF LITERATURE
Review Methods
A search of the literature was conducted on Google Scholar. Using the advanced
search function produced 129 articles that had been published since 2016, 43 articles
since 2019, and 21 articles since 2020, with all of the words: aggressive end-of-life care,
quality goals-of-care discussion, with the exact phrase: quality end-of-life care, with at
least one of the words: hematology hematologist “hematologic malignancies”
“hematologic malignancy” “blood cancer” leukemia lymphoma myeloma, and without
the words: pediatric. The forty-three articles since 2019 were examined for themes and
relevance to the project, then narrowed again to articles without the words: Korean
Brazil, which was the maximum number of characters allowed in that search criteria box.
Further application of exclusion criteria performed through personal review of the 35
remaining articles. Three articles containing “Norway” “Thai” and “Lebanese” were
excluded, one feasibility study was excluded, and 19 documents that pertained to
oncology as a whole or other disease process, were excluded. The 12 remaining articles
were extensively reviewed to extrapolate important topics, data, concepts, and themes.
Additional articles utilized were found through reference-mining, the “cited by” and
“Related articles” feature, and additional searches of terms and/or combination of terms
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from the original 12 articles in Google Scholar, CINHAL, Summons, PubMed, and : endof-life; goals-of-care; hematology; hemato-oncology; blood cancer; advanced cancer;
aggressive end-of-life care; quality, barriers and facilitators of end-of-life; goals-of-care
conversations, discussions; patient-provider communication; prognostication; prognostic
understanding; advance care planning; decision-making; process conversation analysis;
palliative care; goal-concordance; patient- hematologist discordance; hospice; ICU at
EOL; bereaved family member perceptions. One hundred thirty-one items are cited in
this literature review.
History of Dying
Prior to the 20th century, the family commonly provided EOL care at home with
the assistance of visiting health care professionals. In the United States, death at home in
the care of family has been widely superseded by an institutional, professional, and
technological process of dying. This technological process has detached the EOL from
the rest of living (Field & Cassel., 1997). Dr. Cecily Saunders started the modern EOL
movement by establishing the first formal hospice program at St. Christopher's in 1967
(Liegner, 1975). In the same period, Dr. Elizabeth Kubler-Ross sought to understand the
psyche of the dying patient by describing the psychological stages of dying. She also
advocated home, rather than the intensive care unit, as the place of “good death” (KublerRoss, 1969). In 1990, Congress passed the Self-Determination Act, which required
healthcare providers to inquire, inform, and assist patients regarding advance directives.
(Levin, 1990).
Advance Directives
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Unfortunately, despite widespread education and effort, one study in 2010 showed
that, only 26.3% of surveyed adults 18 and older had an advance directive. The most
frequently reported reason for not having one was lack of awareness (Rao et al., 2014).
Another study examined 6,122 Health and Retirement Study (HRS) patients, age 60 and
older, who died between 2000 and 2010. In 2017, a systematic review of 150 articles
published in the period of 2011-2016 was performed in order to determine the proportion
of United States adults with a completed living will, health care power of attorney, or
both. Among the 795,909 people in the 150 studies that were analyzed, 36.7 % had
completed an advance directive, including 29.3 % with living wills. These proportions
were similar across other years reviewed. Similar proportions of patients with chronic
illnesses (38.2 %) and healthy adults (32.7 %) had completed advance directives (Yadav
et al., 2017). A descriptive study of 50 inpatients with high-risk leukemia defined
“complete advance care planning documentation” as in-chart documentation of surrogate
decision maker plus either a written advance directive or documented GOC discussions,
and found that despite very poor prognosis, only 24% of patients had complete advance
care planning documentation in their chart, and only one-third had specific components
of advance care planning addressed. This study was the first study to characterize access
to palliative care and advance care planning by focusing on this high-risk population of
patients with hematologic malignancy and adds to a small but growing body of evidence
showing that patients with varied hematologic malignancies are less likely to have access
to elements of palliative care and advance care planning than patients with solid tumors
(Freeman et al., 2018).
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Kim et al. (2020) explored agreement in EOL treatment wishes in patientcaregiver dyads of patients with hematologic malignancies to find modifiable factors
associated with completion of advance treatment directives. The study found significant
patient-caregiver discordance in treatment wishes regarding CPR, ventilator support,
hemodialysis, and hospice, and noted knowledge about advance directives as the
modifiable factor significantly associated with the completion of an advance directive
(Kim et al., 2020). A study examining 206 patient/oncologist dyads found a majority of
oncologists (76.7%) did not correctly identify GOC that they believed their patients
wanted, indicating they did not fully understand their patients’ GOC, even at the last
meeting prior to death (Douglas et al., 2019). This raises concern that in these cases,
patients are less likely to receive care consistent with their preferences (Desharnais et al.,
2007; Epstein et al., 2016; Gilligan et al., 2017; Mack et al., 2010; Piggott et al., 2019;
Weeks et al., 2012).
Quality End-of-life Care
There is a growing amount of substantiated concern regarding the widespread
provision of non-beneficial, aggressive interventions and costly over-treatment in the
United States at the EOL (Cardona-Morrell et al., 2016; Institute of Medicine, 2015; Lyu
et al., 2017; Mohammed at al., 2019). Treating hospital patients who are on an EOL
trajectory in the same way as those who have a reversible cause for their illness is not
only futile, but also a costly and wasteful form of preventable harm in healthcare (Carter
et al., 2017; Farrell et al., 2008; Smith et al., 2013; Zhang et al., 2009). Still, the
aggressive treatment for terminal advanced cancer patients at the EOL is a common
practice (Mohammed et al., 2019). Health care delivery for people nearing the EOL has
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changed markedly since the Institute of Medicine (IOM) published Approaching Death:
Improving Care at the End of life (1997), however, both research and the everyday
experience of patients, family members, and clinicians suggest that huge gaps remain in
the quality of care for the most vulnerable patients. This poor care continues against a
backdrop of rising health care costs and a sense that patients who account for the greatest
percentage of this expenditure do not benefit from, and may even be harmed by, it's
excess. The report urges a patient-centered and family-oriented approach to EOL care
that honors individual preferences as a national priority and emphasizes the needs for
improved communication about EOL preferences between clinicians and patients (IOM,
2015).
In 2003, Earl et al. generated the earliest set of EOL quality measures for patients
with advanced cancer. These measures, focused on the potential overuse of intensive
care at the EOL and the underuse of hospice services, are now endorsed by national
organizations such as American Society of Clinical Oncology (ASCO) and the National
Quality Forum (NQF) (ASCO Practice Central, n.d; Earle et al., 2004; Earle et al., 2005;
Earl et al., 2008; Grunfeld et al., 2006.; NQF, n.d.). The eight quality measures are as
follows: Hospice >7 days before death; no chemotherapy <14 days before death; no ICU
admission in the last 30 days of life; fewer than two hospitalizations in the last 30 days of
life; fewer than two Emergency Department visits in the last 30 days of life; no intubation
in the last 30 days of life; no CPR in the last 30 days of life; and not dying in an acute
care facility. These measures were later deemed highly acceptable in a large national
cohort of hematologic oncologists and no additional hematologic specific measures were
added to the list (Oderjide et al., 2016). The need to evaluate these EOL quality
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measures for suitability in hematology was determined after several years of data
collection revealed significantly more intensive EOL cancer-directed care (eg. higher
rates of ICU admission in the last 30 days of life, lower rates of hospice enrollment,
fewer days on hospice, and higher rates of chemotherapy close to death) in patients with
hematologic malignancies than in those with solid tumor cancers, suggesting suboptimal
EOL care for this patient population (Earl et al., 2008; Fletcher et al., 2016; Ho et al.,
2011; Howell et al., 2011; Hui et al., 2014; LeBlanc et al., 2015; O’Connor et al., 2014).
The number of days spent at home has been suggested as a potential novel, patient-driven
indicator of quality EOL (Andersen et al., 2019Groff et al., 2016). A large populationbased analysis of 11,127 patients in Ontario, Canada who died from hematologic
malignancies between 2005-2013, found that while over 80% of patients spend greater
than 120 of their last 180 days at home, those with acute leukemias spent the fewest at
home (Cheung et al., 2019)
The benefits of hospice care at the EOL are well established in patients with solid
tumor malignancy and have been shown to improve quality of life for patients and
families, as well as improve family perceptions of quality EOL care and minimize,
psychological distress, risk for depression and post-traumatic stress for the bereaved
(Teno & Curtis, 2016; Wright et al., 2008; Wright et al., 2010) . Barriers to timely
hospice referral and quality EOL care in patients with hematological malignancies
include transfusion dependence, the potential for “cure” despite advanced disease,
uncertainty regarding prognosis, and concerns about affecting patients’ hope, among
other things. Early palliative referral, much like hospice, comes with a stigma in
hematology even though it has been well established to be associated with quality EOL
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(Hui et al., 2015; LeBlanc et al., 2018; Odejide et al., 2016; Odejide & Steensma, 2020).
In the absence of subspecialty referral, evidence has found linking a high level of primary
palliative care (defined as palliative care delivered by the primary transplant/leukemia
physicians) through GOC discussions and/or advance care planning, with high-quality
EOL care outcomes, often with concurrent disease-directed therapy (Lin et al., 2019).
Aggressive End-of-life Care
Adult intensive care unit (ICU) utilization is common near the EOL. In the
United States, approximately 40% of patients die in the hospital, and nearly 60% of these
deaths occur after admission to the ICU, that is, 1 in 5, or 20% of Americans die while
utilizing ICU care (Angus et al., 2004; Seferian & Afessa, 2006). A recent populationbased surveillance, epidemiology, and end results-Medicare database set examined
Medicare beneficiaries who died of hematologic malignancies in 2008-2015 and found
that 33% died in an acute hospital setting, and 36.8% had an intensive care unit
admission in the last 30 days of life or died in the ICU (Egan et al., 2020). There has
been considerable advancement towards patient-centered EOL care in the United States,
but the EOL needs in hematology are unique and make transitions in care settings
challenging. The labor-intensive level of care needed at the end of the disease trajectory
is often beyond the physical and emotional capability of family members, who are often
unprepared and lack the resources necessary to care for someone in that capacity
(Verhoef et al., 2020). Even so, patients and families consistently designate home as the
preferred place of death, but instead, more often die in the acute care setting following
escalating intervention (Chino et al., 2019; Howell et al., 2010; Maddocks et al., 1994;
McGrath, 2002).
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EOL ICU admissions in patients with cancer may be justified to manage
potentially reversible disorders in some patients, however, a significant number of these
admissions are potentially inappropriate, as about half of the ICU admissions for patients
with cancer result in death (Bosslet et al., 2015; Kress et al., 1999; Thiery et al., 2005;
Weir et al., 2014). Despite remarkable treatment advances, many hematological
malignancies remain incurable, have unpredictable/uncertain trajectories, and have highly
variably outcomes, which can be particularly poor for some karyotypic subtypes.
Deterioration is often sudden and unexpected, manifesting as relapse or a devastating
failure to respond to one or more lines of intense standard of care chemotherapy regimens
(Roman et al., 2016; Smith et al., 2015; Swerdlow et al., 2016). Moreover, patients with
hematological malignancies are often treated with multiple new, experimental, and
intense antineoplastic regimens with significant or unknown toxicities, and those
treatments may continue until the last days of life (Hui et al., 2010; Hui et al., 2013;
Sanchez-Cuervo et al., 2020). Clinical trial participation is significantly associated with
aggressive EOL care, intensive care unit death, and inferior quality of life near death
(Enzinger et al., 2014). Understandably, these patients and their caregivers frequently
experience psychological distress (Bishop et al., 2007; Rodin et al., 2013).
Caregivers often indicate dissatisfaction with the care provided to their loved ones
at the EOL. Shirai et al (2016) published the first quantitative study evaluating care for
myelodysplastic syndrome/leukemia and lymphoma patients during their last
hospitalization. They found that 57% of caregivers were not satisfied with the care
provided and a “good death” was often not achieved (Shirai et al., 2016). A similar
study, also published in 2016, examined family perspectives of older patients with fee-for
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service Medicare who died of lung or colorectal cancer, and linked perception of better
EOL care to earlier hospice enrollment, avoidance of ICU admissions within 30 days of
death, and death occurring outside the hospital (Wright et al., 2016), while another study
found that one in 8, or 13% of bereaved family members report that care in the last month
of life was not consistent with the decedent’s wishes (Khandelwal et al., 2017).
McCaughan et al. (2019) examined preferred place of care and death in patients with
blood cancers from the perspectives of bereaved relatives and found that, while home is
overwhelmingly the preferred place of death, the hospital was sometimes preferred and,
on reflection, some relatives identified this as the “right” place for the patient to have
died. Factors impacting achievements of home death where disease characteristics, the
occurrence and timing of EOL discussions, family networks and resource availability.
Early, honest and realistic communication of risk and uncertainty, initiated by
hematologist, could prevent over-optimism and facilitate advanced planning among
patients and relatives, as well as allow primary care staff adequate time to prepare for the
patient’s potential death at home.
Patient-Clinician Communication
The Institute of Medicine’s (IOM) 2015 report on approaching death called for a
transformation in how we care for the dying in this country, emphasizing the need for
improved communication about EOL preferences between clinicians and patients (IOM,
2015). Improved health care communication has been associated with improvements in
many different objective and subjective health outcomes, including blood pressure
control, hemoglobin A1C and diabetes, adherence to medication use, and patient
satisfaction (Hojat et al., 2011; Slatore et al., 2010; Stein et al., 2005; Stewart, 1995;
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Zachariae et al., 2003; Zolnierek & Dimatteo, 2009). Communication in oncology
practice presents numerous challenges and although studies show that most patients want
their oncologists to discuss EOL plans, these conversations often do not occur (Barakat et
al., 2013; Mack et al., 2010; Wright et al., 2008). Healthcare providers often do not
discuss GOC with seriously ill hospitalized patients (Anderson et al., 2011; Hofmann et
al., 1997) or they approach them inadequately (Deep et al., 2008; Osborn et al., 2012),
contributing to provision of high intensity care in the final months of life, even when
patients and caregivers prefer treatments focused on comfort and quality of life
(Covinsky et al., 2000; Heyland et al., 2006; Wenger et al., 2000; Yuen et al., 2011).
Mounting evidence suggests that aggressive EOL cancer care is a modifiable
trend, and that earlier discussions between patients and their physicians regarding EOL
preferences could be associated with less aggressive and less costly care near death
(Mack et al., 2012; Roman et al., 2019; Starr et al., 2019; Wright et al., 2008; Wright et
al., 2010; Weeks et al., 1998; Prigerson, 1991). In 2017, The American Society of
Clinical Oncology (ASCO) released consensus guidelines regarding patient-clinician
communication with recommendations that addressed specific topics, such as discussion
of GOC and prognosis, treatment selection, and EOL care in addition to providing
guidance regarding core communication skills and tasks that apply across the continuum
of cancer care (Gilligan et al., 2017).
Barriers to GOC and EOL discussions in oncology are widely acknowledged and
researched, they include but aren’t limited to unrealistic patient expectations, clinician
concern about taking away hope, and unrealistic clinician expectations (Odejide et al.,
2016). Many patients may not be aware of the dismal prognosis of their cancer, due to
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lack of understanding or omission of information by their providers. In addition, GOC
are too often not addressed for patients at high risk of death (El-Jawahri et al., 2017).
Patients with metastatic solid tumors typically have a more indolent course of progression
compared to patients with hematologic malignancies, and one study found only 4% of
patients with hematologic malignancies (vs 23.5% of solid tumor patients) had discussed
GOC or code status within the last month before their terminal ICU admission (Heng et
al., 2020).
Several researchers agree that hematologists possess certain personality traits and
practice paradigms that yield very specific barriers to having GOC and EOL discussions
that are not fully understood, and that research on this phenomenon is needed.
Prod’homme et al (2018) recently published a qualitative grounded theory study using
individual interviews to give rare insight into these hematologist-specific barriers.
Hematologists describe particular issues, such as the difficulty for individual
prognostication due to the chemo-sensitivity of hematological malignancies, and the
possibility of allogeneic stem cell transplantation that allow ongoing therapeutic goals of
curable or long-term survival. In contrast, acute complications are frequent, unpredictable
and change the prognosis rapidly. Often the acute complications may contribute to death
before the possible involvement of a palliative care team. Furthermore, long relationships
develop between patients and their hematologists, and the negative representation of
palliative care contributes to lack of referral (Gatta & LeBlanc, 2020). Prod’homme et
al.’s (2018) study uses qualitative grounded theory and individual interviews to identify
barriers and explore ten hematologists’ thought logic. The qualitative analysis found
barriers to EOL discussions could be grouped into three main categories: the
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hematologist’s desire to help patients fight-for-life, the hematologist’s own perception of
what is good for patients, and the hematologist’s difficulty with incertitude (Prod’homme
et al., 2018). Additionally, issues with accurate prognostication in the era of exceptional
responders, patient prognostic understanding, discordant GOC, and identification of when
EOL begins, have been described (Odejide et al., 2014; LeBlanc et al., 2018; Loh et al.,
2019).
Fight-for-Life
Prod’homme et al. (2018) recognize that Hematologists’ view talking about death
as stressful, difficult, and taboo in a recent study. The 2018 study found that physicians
often adopt a false positive attitude with their patients in order to avoid the subject of
death. They do this by leavings things unsaid, being ambiguous, and omitting certain
information. According to them, in the event of recurrence, their responsibility is to
reassure their patient with a positive attitude, re-inspire the confidence that was lost when
the disease recurred, and provide motivation; this role was not felt to be compatible with
conducting an EOL discussion. As long as hematologists have therapeutic options to
treat blood-related cancer, they seem unable to open discussions about EOL. Some
believe imminent death is proof of professional failure, and fear things such as loss of
credibility, jeopardizing patient compliance or patient-physician relationship, and
potential negative effect on treatment success and tolerance (Prod’homme et al., 2018).
Hematologists own Perceptions of What is Good for Patients
The willingness of hematologists to consider patient perspectives for the future
and talk about EOL is restricted by their desire to maintain patient-physician relationship
when a recurrence occurs. In fact, the main factor that contributed to begin an EOL
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discussion was an explicit request coming from the patient. Even then, the hematologists
aimed to provide a certain degree of psychological security for the patient, and endorsed
probing to see what the patient wants, leaving the door open to conversations, and testing
the patient to see whether or not they really wanted to receive an answer. They seek to
protect their patients from violent and EOL discussions at the time of recurrence, and
often representations of what they feel is best for the patient is defined according to the
hematologist’s own ideals about health care and EOL (Prod’homme et al., 2018). An
example of this issue is often seen at diagnosis of acute myeloid leukemia (AML).
Hematologists know that understanding the biology of AML has led to therapeutic
interventions potentiating meaningful responses with more acceptable toxicity profiles
compared with intensive therapy. Nevertheless, the diagnosis often comes late in life
when patients are more likely to have impaired functional status and suffer from other
comorbid illnesses. Therefore, the oncologist must be unbiased and fully engaged with
the patient, discussing goals of therapy and EOL issues, in a shared decision-making
process (Leblanc & Erba, 2019).
Difficulty with Incertitude, Hope, and Clinical Trial Participation
For hematologists, having and EOL discussions and collaborating with palliative
care teams is equivalent to affirming that the outcome is inevitably fatal, and therefore
incompatible with hope. Certainty of imminent death is the preferred incentive for EOL
discussion. Incertitude and hope of remission, however slight, stops any discussion about
the threat of death or advance care planning (Prod’homme et al., 2018).
For patients with advanced refractory cancer, experimental therapy, particularly
on an early phase clinical trial, is a common therapeutic option (Nurgat et al., 2005).
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Although the principle purpose of clinical trials is to generate knowledge to improve
future therapy, many patients incorrectly believe that the primary purpose is to directly
benefit participants (Joffe & Weeks, 2002; Peppercorn et al., 2004). Classic Phase I trials
are designed with nontherapeutic primary aims of determining toxicity and the optimal
dose for subsequent testing and infrequently provide direct benefit (Horstmann et al.,
2005; Roberts et al., 2004). Unfortunately, most patients misunderstand the purpose of
early phase trials, and enroll anticipating a substantial likelihood of personal benefit, even
cure, rather than for altruistic reasons (Daugherty et al., 1995; Meropol et al., 2003;
Nurgat et al., 2005; Sulmasy et al., 2010; Truong et al., 2011; Weinfurt et al., 2003;
Weinfurt et al., 2008). Nevertheless, several highly successful early-phase trials
involving targeted cancer therapies demonstrated that drugs in early development can
occasionally provide significant benefit to patient-subjects (Flaherty et al., 2010; Kwak et
al., 2010; Topalian et al., 2012).
Many patients with very limited life expectancy are highly motivated to continue
disease-directed treatment and pursuing investigational therapy may help them and their
loved ones feel they have fought their best fight, thereby finding greater acceptance and
peace at the EOL (Agrawal et al., 2006) Conversely, trial participation might distract
some patients from coming to terms with death and making EOL plans. National
guidelines support balancing hope and desire for more treatment with other EOL GOC,
including symptom control, avoiding futile interventions, and supporting the patient's
ability to come to terms with and prepare for death (Peppercorn et al., 2011; Steinhauser
et al., 2000; Temel et al., 2011; Wright et al., 2008).

31

Accurate Prognostication in the Era of Exceptional Responders, Prognostic
Understanding, and Discordance in Perceived Chance of Cure
Understanding one's prognosis is fundamental to making informed treatment
decisions. Novel immunotherapies and genome-targeted treatments, which yield
exceptional responses and a small proportion of patients, further complicates
hematologists’ ability to formulate and communicate prognosis to patients with advanced
disease. Existing approaches to improving patient clinician communication in
hematology are inadequate to accommodate different levels of skill and aptitude among
practicing hematologists (LeBlanc et al., 2018). One study found that over 90% of
hematologists report initiation of prognostic discussions at diagnosis, but only 17.7%
readdressed prognosis until death was imminent (Habib et al., 2019). If, by chance, a
hematologist is able to articulate accurate prognostication, often time patients report an
inaccurate perception of their prognosis. Prior studies have demonstrated that up to 82%
of patients with hematologic malignancies have a different understanding of their
prognosis compared with their hematologist (El-Jawahri et al., 2015; El-Jawahri et al.,
2019: Lee et al., 2001; Sekeres et al., 2004). Much of this discordance is skewed toward
optimism, meaning that patients tend to have higher expectations for cure, which has
significant implications for care received. The discordance may be related to patient,
physician, and/or societal factors, but the optimism motivates patients to opt for more
aggressive care (Chen et al., 2017; Chochinov et al., 2000; Derry et al., 2019; Gramling
et al., 2016; Henselmans et al., 2017; Loh et al., 2019; Mack et al., 2015; Robinson et al.,
2008).
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The availability of novel, efficacious treatments is changing the landscape of
cancer therapeutics and dramatically improving prognosis in a subset of patients with
advanced disease. As hematologists, it is gratifying and exciting to administer therapies
such as immune checkpoint inhibitors to patients who previously had a prognosis of less
than one year, and occasionally to see their cancer remain quiescent for many years
(Wolchok et al., 2017). Unfortunately, many patients do not respond to immunotherapy,
have underlying health conditions, or experience toxicities that prohibit administration.
The availability of these novel therapies is making the already significant problem of
communicating prognosis more complex (Elias, 2019; LeBlanc et al., 2018).
Identification of When End of Life Begins
The studies raising concerns about the quality of EOL care for patients with blood
cancers provide little insight into the associated perceptions and decision-making
processes of the hematologic oncologists involved in their care. In addition, little is
known about how to define the “EOL phase” for these patients. Participants in four focus
groups from the Dana Farber/ Harvard Cancer Center indicated that identifying when the
EOL phase of blood cancer begins is challenging (Odejide et al., 2014). Uncertainty
regarding prognostication centered on several factors. First, providers for patients with
leukemia, lymphoma, and hematopoietic stem cell transplantation specified that
possibility of cure for many hematologic malignancies, even in relapse states, makes it
difficult to prospectively determine when the EOL phase of disease begins. This was
specifically noted as a salient difference between blood cancers and the majority of
advanced (Stage IV) solid malignancies, which are incurable. As one participant
explained, “For metastatic lung cancer, there is no tail on the survival curve pretty much.

33

Whereas with lymphoma although most patients with refractory disease will likely die,
we all know there is a tail...through allotransplant” (Odejide et al., 2014 p. e398).
Participants agreed that although the median survival for many hematologic malignancies
may not differ from advanced solid malignancies, the potential for cure, even when small,
impacts their ability to accurately determine when a patient is at the EOL (Odejide et al.,
2014). For this reason, interdisciplinary cooperation, timely discussions about specialist
palliative referral, and indicators to ‘flag' patients in need of specialist or primary
palliative care are important, but they are largely missing and further models of early
integrated palliative care should be evaluated in prospective studies, and established in
daily clinical practice (Oechsle, 2019).
Summary
While the research has described several EOL quality indicators, in order to affect
change, one must intervene with specific interventions that aggressively address one issue
at a time. Administrative and stakeholder input have focused this researchers’ effort on
reducing ICU admission in the last 30 days of life and EOL healthcare costs, while
increasing the quality of EOL care provided in a tertiary inpatient hematological research
facility. While researching and synthesizing the available information, the root cause of
aggressive EOL care has been identified and described in this literature review, leading to
establishment of potential interventions to address existing gaps and shortcomings in
common practice, namely, having and documenting earlier GOC and EOL discussions in
patients with hematologic malignancies.
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CHAPTER III
METHODS/PLAN
Introduction
Practice problems are often large, polymorphic, system-wide issues with unclear
solutions. For this reason, a mixed-method study that examined the discussion and
documentation compliance rates while also exploring perceived barriers in cases of noncompliance provided benefits drawn from the potential strengths of both quantitative and
qualitative methods. Mixed-methods research enabled the researcher to explore diverse
perspectives and uncover relationships that exist between the intricate layers of the multifaceted research questions. The purposeful mixing of methods in data collection,
analysis, and interpretation of evidence fostered data linkage and integration between
rates of pathway utilization and perceived barriers, therefore enabling a panoramic view
of the research problem.
Benchmark data shows that patients with hematologic malignancies receive more
aggressive care at the EOL and have higher rates of ICU admission in the last thirty days
of life, which is associated with poor quality EOL care (Wright et al, 2016). A task force
convened to address this issue and created a GOC pathway that could endorse goal
concordance. The rollout of the project was poor, uncommunicated, and did not utilize
APP involvement or leadership. There was an e-mail with a very lengthy document and
35

the project came as a surprise both to hematologists and inpatient APP’s, who were not
educated on the importance or reasoning behind the new pathway.
Project Design
This study sought to answer five research questions:
1. How many leukemia inpatients met the established GOC pathway criteria for poor
prognosis upon admission during the months of October 2020 and January 2021?
2. How many poor prognosis leukemia inpatients admitted in October 2020 and
January 2021 had appropriate referral for GOC pathway?
3. How many poor prognosis leukemia inpatients admitted in October 2020 and
January 2021 had a properly documented and billed GOC discussion utilizing the
approved template prior to hospital discharge or death?
4. How do the hematologists define “GOC conversation” in one sentence and what
do they consider the most important components?
5. What do the hematologists identify as perceived barriers in having/documenting
GOC conversations?
It was suspected that compliance with the GOC pathway was low, which indicated
the need for evaluation and adaptation. The CFIR will serve as a roadmap for pathway
project evaluation and data gathered in this study will provide valuable information to fill
in existing gaps in knowledge of the 5 domains of the CFIR. These gaps are italicized in
Figure 6.
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Figure 6
Consolidated Framework for Implementation Research

Intervention
Characteristics
(Stakeholder
perception)

• Intervention source- Negative perceptions regarding
development and legitimacy exist.
• Evidence Strength and Quality-Negative belief that the
intervention will have desired outcomes.
• Relative advantage- Perspectives regarding the advantage
of implementing the intervention versus an alternative
solution.

Outter Setting

• Patient need is present and proven. GOC conversations are
not being had and prognostic discordance exists.
• Peer Pressure- competition to remain "the best in the west."
• Governmental and external mandates, recommendations,
tuidelines, pay-per-performance, benchmark reporting.

Inner Setting

• Difference in opinion and vision of various hematologists
• Poor communication vs too much communication
impersonal (Zoom) communication.
• Collaboration and open feedback
• Culture, norms, values, and basic assumptions
• Implementation climate- capacity for change, shared
receptivity of involved individuals to the intervention.
Prioirity, incentive, readiness.

Characteristics
of Individuals
Involved

• Knowledge, skill, beliefs, opinions, experiences of
individuals.
• Attitude and value placed on GOC discussions.
• Individual belief in their own capabilities, self-efficacy.
• Hematologist stage in progression toward sustained
committment to GOC conversations in poor prognosis
patients.

Implementation
Process

•
•
•
•

Planning
Engaging
Executing- Quality of execution
Reflecting and evaluating- QUANTITATIVE AND
QUALITATIVE FEEDBACK ABOUT THE PROGRESS
AND QUALITY OF IMPLEMENTATION= MIXED
METHODS ANALYSIS
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This study used a mixed-methods, explanatory sequential design (follow-up
explanations variant) to explore the phenomena of hematologists’ aversion towards GOC
conversations in the inpatient setting. This study design provided a more comprehensive,
in depth understanding of the practice problem and resulted in a framework of evidence
to be used in project implementation evaluation. All qualitative data was obtained using
an anonymous SurveyMonkey platform to promote participation.
Once the project was approved for exempt status by both the facility’s IRB and
the academic institution, retrospective chart review by the researcher first quantified the
degree of compliance that currently existed in referral of criteria-specified poor-prognosis
patients for goals discussions via the GOC pathway, and hematologist compliance in
having/documenting/billing for goals discussions in these patients. Percentages from the
facility in which the hematologists practice described the issue as it pertains to them more
than nation-wide percentages that are published. Compliance was not monitored or
manipulated in real-time or influenced by the researcher. However, the researcher
remained an established resource if the hematologist chose to reach out and request
assistance or guidance. The quantitative data answering research questions 1, 2 and 3
was initially intended to be included in the letter to the hematologists containing the
Survey Monkey link requesting qualitative answers to research questions 4 and 5,
however, after reviewing the data, it was decided that inclusion of this information may
discourage truthful response to the survey questions.
Sample/Target Population
The study was designed with an identical mixed-method sampling design because
the same people were to be used in both strands of the study. The intent of the qualitative
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component was to offer detail and elaboration about phenomena that was captured
quantitatively. Recruitment for the study consisted of the eighteen hematologists
practicing in a southern California dedicated cancer research center, that specializes in
hematology, largely leukemia, and other diseases that may be cured with allogeneic
hematopoietic stem cell transplant. These eighteen hematologists rotate through four
leukemia services on a two-week rotation schedule. Permission was received from both
the institution’s IRB and the academic entity’s IRB. Participation in survey completion
was anonymous and voluntary.
The pathway was created to initiate GOC conversations between hematologists and
patients with a poor prognosis based on the following criteria:
1) Leukemia/ myelodysplastic syndrome (MDS) with relapsed or refractory disease
after one line of treatment.
2) Multiple myeloma or lymphoma with relapsed or refractory disease after two
lines of treatment.
3) Excluding those admitted for a potentially curative treatment such as allogeneic
stem cell transplant, chimeric antigen receptor T-cell therapy (CAR-T) and
autologous transplant.
The study sought to explore leukemia physicians, therefore, only patients
identified by the first criteria were initially considered for inclusion in the quantitative
data collection. However, in response to an administrative request to the task-force, all
inpatient admissions meeting either criteria were included in the quantitative results.
The established GOC pathway protocol excluded patients who were admitted for curative
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treatment such as hematopoietic stem cell transplant, and those admitted to receive
treatment under some specific IRB protocols with targeted therapies, and CAR-T.
Inclusion & Exclusion Criteria. Only the eighteen hematologists at this facility
who specialized in leukemia and rotated through the four leukemia services were
included in the qualitative arm of this study. No lymphoma, myeloma physicians or
APPs were asked to participate.
Ethics and Protection of Human Subjects. Prior to data collection, approval
was obtained from the Pittsburg State University Irene Bradley School of Nursing
Institutional Review Committee and the dedicated cancer center’s IRB. The proposed
quantitative research involved retrospective chart review of all patients admitted to the
hematology service during the months of October 2020 and January 2021, involved no
procedures for which written consent is normally required outside of the research context,
and the research presented no more than minimal risk of harm to subjects.
The researcher initially applied for expedited IRB approval by submitting the
Expedited Review of Research Involving Human Subjects Criteria Form, The
Application for Approval of Investigations Involving Human Subjects, and the
Application for Waiver of Informed Consent Form to the Pittsburg State University
Office of Graduate and Continuing Studies and the Pittsburg State University Committee
for the Protection of Human Research Subjects (CPHRS), after these documents
underwent review and were approved by the Pittsburg State University Irene Ransom
Bradley School of Nursing. The request was modified to exempt after receiving exempt
approval from the cancer institution’s IRB. Participation in the qualitative
SurveyMonkey was voluntary and anonymous, which was explained in a “pre-mail” sent
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to the leukemia division three days prior to sending the official study request with IRB
approved consent, cover letter, and survey link. The purpose of the study, voluntary
nature of the study, and intended use of the information received was again explained,
along with the steps taken to protect respondent anonymity, in the official study request
e-mail containing the consent and link to the survey. The responses were kept
anonymous in the survey monkey and the researcher did not share login or password to
their account containing the survey results.
Biases. Biases are a potential barrier in any qualitative exploration of human
feelings. Even though anonymity was practically guaranteed, there was still a risk that,
consciously or subconsciously, the hematologists would distort their responses to present
themselves in the best light or simply because they were unaware of their own behavior
and biases.
Instruments
The quantitative data was obtained with retrospective chart review by the
researcher. Information was entered into an Excel document consisting of columns:
Admit Date, Service, Admitted for, Meets criteria (Y/N), Why?, SW Consult placed
(Y/N), Consult date, Location at time of consult, Meeting occurred (Y/N), Proper
documentation of GOC meeting under ACP notes using approved template (Y/N), ACP
charge present during admission (Y/N) , and an opt-out criteria/ Misc extra information
column for notes the researcher considered potentially useful in analyzing and
understanding the problems surrounding GOC discussions. The spreadsheet was later
condensed for ease of analysis and the why, consult date, location at time of consult, and
opt-out criteria/misc extra information columns were removed. All information was
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stored on facility locked computer in the approved OneCloud drive for Business under
the researcher’s institutional account. The Doctor of Nursing Practice (DNP) student
researcher is employed by the facility, has access to the charts and no HIPPA violations
took place. The patient MRN was the only identifier and only identifiable by a current
employee with Epic access, however, under the recommendation of the facility’s IRB, the
MRN was removed from the data collection spreadsheet prior to saving the document
each time it was accessed.
The qualitative instrument was a survey (Appendix C), hosted by
SurveyMonkey.com and consisted of two exploratory open-ended questions aimed to
provoke deep thought and explore the personal opinions and beliefs of the hematologists
in an anonymous form. Content validity was established after review from institutional
APP and MD leadership, and scholarly project committee, consisting of two doctorly
prepared APP’s and a statistician. The hematologists were informed of the DNP
researcher’s intent to publicize the de-identified qualitative findings in fulfillment of the
DNP scholarly project, and that the information would be used to modify the current
protocol at their facility based on what was learned.
Procedure and Implementation Plan
After project approval was obtained from both academic and research facility
IRB, retrospective chart review was performed on each patient admitted to the
Hematology and Hematology Transplant Readmit services during the months of October
2020 and January 2021. The charts were personally accessed by the DNP student
researcher, who is an employee of the site facility. The history and physical were first
examined to determine reason for admission, treatment history, and current disease status.
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Patients who were admitted to one of the leukemia services and identified as poor
prognosis by the first criteria stated above, underwent further chart review to determine
presence of correct social work order to initiate GOC pathway, presence/absence of
properly documented GOC conversation, and advanced care planning charge using CPT
code 99497 or 99498. The DNP student researcher worked closely with social worker
who tracked the presence or absence of GOC meetings in all inpatients who had the GOC
pathway initiated via social work order. The social worker’s data was compared against
the researchers data to verify consistency and validity of certain research findings. An
Excel spreadsheet (described above) was stored on the secure institutional OneDrive for
Business, which is the institutional-wide approved storage cloud that allows the safe
construction, storage, sharing, and editing of documents that may contain confidential
patient information. Once all patient charts admitted during the two-month time frame
were examined and findings placed in excel, assistance was solicited from a colleague
experience in Excel to guide in utilization of Excel features for data extrapolation and
analysis. Additional assistance was provided through program help functions and videos.
Figure 7 illustrates the final collection method of extrapolated data.
Figure 7
Raw Data from Chart Review
Admit
Service
Date
##/##/#### Leuk
1,2,3,4

Admitted Criteria
for
………
Y/N

SW
Cons?
Y/N

Meeting? ACP
doc?
Y/N
Y/N

ACP
Charge?
Y/N

Though originally intended to be included with the cover letter, the researcher
opted out of including the quantitative date in the cover letter that requested survey
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completion. It was thought the results may be threatening to the hematologists as they
indicated very poor compliance with the pathway and GOC initiative. It was shared that
the information obtained would be used to develop strategies to address the well-known
aversion to GOC conversations in hematology. The survey was kept open for ten days
and reminder e-mails containing the survey link were sent out every 3 days and on the
day of survey closing. The service line director offered to “nudge” the hematologists, but
the researcher declined their offer to protect the integrity of the responses. Ten days after
the initial e-mail, the survey closed. Then, extrapolation and analysis of the qualitative
data began with the assistance of a PhD prepared NP, a statistician, a DNP mentor, and
other experts.
Consent was assumed with completion of the survey though a very detailed
institutional consent form was required by the facility’s IRB. It was assumed that each
hematologist would be ethical and complete the survey only one time, and do so honestly
During the planning process, the researcher considered the limitations within the
sample population concerning generalizability, however, it was the intent of the
researcher to limit the findings to this specific population in order to obtain meaningful
data that could be used to construct tailored solutions. Also, due to the known
phenomenological aversion of hematologists to GOC discussions, there was a concern
that there may be a lack of response to the survey.
Treatment of Data/Outcomes/Evaluation Plan
Analysis of Data. This was an explanatory sequential design research study, and
the integration intent was to connect the results and provide a strong explanation for the
compliance rate of GOC conversations in hematologists. Descriptive statistics were used
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to analyze and report the quantitative data obtained from chart review and report level of
compliance or non-compliance. The inductive qualitative analysis used tags and content
analysis to identify themes and categories for each of the open-ended questions of the
survey so that an in-depth understanding of the phenomenon could be learned.
Evaluation Measures. Outcome and evaluation measures were correlated with
the project research questions, objectives established in the logic model (see Figure 4)
and goals established in the short, medium and long-term outcomes (see Figure 5). The
survey instrument was intended to provoke thoughtful, meaningful responses in a nonthreatening and anonymous form. Project quality was based on criteria for doing highquality mixed methods research, as proposed in many frameworks in Fabregues and
Molina-Azorin’s (2017) review. The study met the following five criteria:
1. A strong rationale existed for collecting and analyzing both quantitative and
qualitative data.
2. The quantitative and qualitative strands were well implemented and adhere to
the quality criteria of each tradition.
3. The quantitative and qualitative components of the study were well integrated.
4. The sampling, data collection, and data analysis procedures for both strands
were linked to the study intent and the research questions.
5. Inferences were consistent with the study findings and with the study intent.
Plan for Sustainability
In 1987, the United Nations General Assembly issued the report of the world
Commission on Environment and Development. The report described sustainability as
“meeting our own needs without compromising the ability of future generations to meet
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their own needs, considering social and economic resources in addition to natural
resources.” Healthcare in its current state in America is not sustainable at this point and
change needs to occur. This research project was developed to contribute, in part, to
healthcare sustainability by reducing the unwanted and unnecessary use of medical
resources that is currently straining our system. By establishing clear goals based on
prognostic understanding, patients and providers with goal concordance can make shared
decisions that reflect the patient’s values, beliefs and desires, especially at the EOL,
which is when a person typically uses the most health care resources. Both political and
financial components necessitate sustainability of this, and other projects aimed at
reducing unwanted and unnecessary EOL healthcare usage.

46

CHAPTER IV
FINDINGS
Patients with hematologic malignancies often receive aggressive care at the EOL,
leading to lower quality of life. Aggressive EOL care in patients with advanced-stage
cancer is increasing despite growing concerns that this reflects poor-quality care (Wright
et al, 2016). Furthermore, studies have found that, regardless of illness, at least 13% of
the time, the EOL care provided is inconsistent with the patients’ GOC and causes
psychosocial and financial burden to the family (Khandelwal et al, 2017).
In April of 2020, a freestanding U.S. academic cancer hospital launched a pilot
GOC pathway project ultimately aimed at improving goal concordant care. The pathway
identifies “poor prognosis” patients admitted to the hospital based on hematologic
disease-specific criteria. The original task force did not include APP leadership or
representation during the planning phase, which resulted in an unsuccessful first roll-out.
Fortunately, a DNP student leader saw this as an opportunity to prove APP input as a
necessity for program success. The project objectives were modified to include “discover
actual and potential NP contribution to the GOC pathway pilot project” and, after weeks
of multi-disciplinary collaboration, the pathway pilot was re-launched with several
revisions that gave ownership to the inpatient APPs.
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The Alliance of Dedicated Cancer Centers (ADCC) represents the ten
freestanding U.S. academic cancer hospitals, and this alliance developed a national
implementation initiative to enhance goal-concordant care for patients with cancer. The
initiative recognizes and embraces the vision that all patients with cancer and their
families should receive care that aligns with their values and unique priorities. In
September 2020, the ADCC released the Improving Goal Concordant Care (IGCC)
Initiative Implementation Planning Guide, which was created to address system gaps in
the centers and to establish new expectations for when and how GOC conversations
occur. This placed the DNP student researcher and the GOC pathway project at the
center of the institution’s plan for a nationwide quality improvement initiative.
When rolling out a practice changing initiative, it is important to monitor progress
for unanticipated influences (barriers and facilitators) and progress toward
implementation goals (Damschroder et al., 2009). The implementation of this practice
transformation initiative needed to be evaluated. The CFIR is the theoretical framework
that was chosen to serve as a roadmap for pathway project evaluation and the data
gathered in this study provided valuable information to fill existing gaps in the
knowledge of the 5 domains of the CFIR.
Purpose
The first purpose of this scholarly project was to evaluate participation of APPs
and physicians in the GOC pathway process and using a quantitative method of study.
The second purpose used a qualitative study design to explore hematologists’ self-reports
regarding their knowledge, opinions and barriers surrounding GOC discussions and the
proper billing of these conversations.
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Project Questions
1. How many leukemia inpatients met the established GOC pathway criteria for poor
prognosis upon admission during the months of October 2020 and January 2021?
2. How many poor prognosis leukemia inpatients admitted in October 2020 and
January 2021 had appropriate referral for GOC pathway?
3. How many poor prognosis leukemia inpatients admitted in October 2020 and
January 2021 had a properly documented and billed GOC discussion utilizing the
approved template prior to hospital discharge or death?
4. How do the hematologists define “GOC conversation” in one sentence and what
do they consider the most important components?
5. What do the hematologists identify as perceived barriers in having/documenting
GOC conversations?
Quantitative Sample/Results
The first 3 project questions were answered with quantitative examination of data
that was obtained via chart review of the inpatient admissions for October 2020 and
January 2021 (see Table 1). For both months, only patients admitted to the Hematology
Transplant Readmit or Hematology service were eligible for inclusion. Admissions to
the Bone Marrow Transplant (BMT), breast, colorectal, endocrinology, Emergency
Treatment Center (ETC), extended recovery, gastroenterology, gynecologic oncology,
integrated care services, internal medicine, interventional radiology, medical oncology,
neurosurgery, oncology, orthopedics, otolaryngology head and neck, PED transplant,
pediatric transplant readmit, pediatrics, plastic surgery, surgery, surgical oncology,
thoracic surgery and urology services were excluded.
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Table 1
Research Questions 1, 2, 3
Question Number
1. How many leukemia inpatients met the established GOC
pathway criteria for poor prognosis upon admission during the
months of October 2020 and January 2021?

Results- ResultsOctober January
63
68

2. How many poor prognosis leukemia inpatients admitted in
October 2020 and January 2021 had appropriate referral for
GOC pathway?

19

10

3. How many poor prognosis leukemia inpatients admitted in
October 2020 and January 2021 had a properly documented and
billed GOC conversations utilizing the approved template prior
to hospital discharge or death?

19

1

October 2020
The Tableau Dashboard in Epic was used to sort the patients by month of
admission and service. For the month of October 2020, each of the 721 total admissions
were reviewed, 623 were inpatient admissions and 98 were observation. At the time of
the initial access and chart review, 206 patients were admitted as an inpatient to either the
Hematology service or the Hem Transplant Readmit service, and 8 patients were
admitted to these services under observation during the month of October 2020. Of these
206 admissions, 4 Kaiser admissions, 1 Coronavirus-19 (COVID) admission, and 8 CART admissions were excluded. Of 193 eligible encounters, 63 (33%) patients met criteria
for GOC pathway initiation and 130 (67%) did not (Figure 8).
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Figure 8
October 2020 Admissions Data

October, 2020
206 Admissions

Did not Meet
Criteria, 130, 67%

KAISER, 4, 2%
COVID, 1, 0%
CAR-T, 8, 4%

Eligible
Encounters,
193, 94%

CAR-T
COVID
KAISER

Met Criteria, 63,
33%

Did not Meet Criteria
Met Criteria

Of the 63 patients who met criteria for initiation of the GOC pathway, 19 had an
appropriate social work consult to initiate the pathway and 4 of those had appropriate
documentation and billing for a GOC discussion by the physician. Of the 44 patients
without appropriate consults placed, 2 eventually had consults upon ICU admission via
the ICU pathway and one had a supportive care medicine consult. Forty-one patients
who met criteria did not have a social work order or a documented GOC discussion at
any point during that admission encounter (Figure 9).
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Figure 9
October 2020 Admissions Meeting GOC Pathway Criteria

October, 2020
63 Encounters Met Criteria
ICU/SCM Pathway,
3, 5%

Did not have Consult

ICU/SCM Pathway
No ACP note or charge
Proper Note/Charge

SW consult to
initiate pathway,
19, 23%

No ACP note or
charge, 15, 79%

Proper
Note/Charge,
4, 21%

Did not have
Consult, 41, 72%

January 2021
In January 2021, 230 patients were admitted as an inpatient to the Hematology
service or the Hem Transplant Readmit service. Excluding the 11 CAR-T admissions, 3
Kaiser admissions and 40 COVID admissions, 176 admission encounters were eligible
for inclusion in this study. Sixty-eight (39%) patients met the criteria for initiation of the
GOC pathway and 108 (61%) did not (Figure 10).
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Figure 10
January 2021 Admissions Data

January, 2021
230 Admissions

Did not Meet
Criteria, 108, 61%

KAISER, 3, 1%
COVID, 40, 17%
CAR-T, 11, 5%

Eligible
Encounters,
176, 77%

CAR-T
COVID
KAISER

Met Criteria, 68,
39%

Did not Meet Criteria
Met Criteria

Of the 68 encounters that met criteria for GOC pathway initiation, 10 (15%) had a
social work order placed to initiate the pathway. Fifty-three (78%) did not have an order
or documented discussion at all, and 5 (7%) had an order placed upon ICU admission via
the ICU GOC pathway. Of the 10 encounters with appropriately placed pathway orders,
9 (90%) had no Advance Care Planning documentation and no Advance Care Planning
(99497 or 99498) charge during that admission and only 1 (10%) had an appropriately
documented and billed GOC discussion by the hematologist (Figure 11).
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Figure 11
January 2021 Admissions Meeting GOC Pathway Criteria

January, 2021
68 Encounters Met Criteria

Did not have Consult

ICU/SCM Pathway

ICU/SCM Pathway,
5, 7%

No ACP note or charge
Proper Note/Charge

SW consult to
initiate pathway,
10, 15%

No ACP note or
charge, 9, 90%
Proper Note/Charge,
1, 10%

Did not have
Consult, 53, 78%

Qualitative Sample/Results
Project questions 3 and 4 required a descriptive qualitative inductive design that
utilized content and thematic analysis of data that was obtained via an anonymous
SurveyMonkey survey with two open ended questions (see Appendix C). The
anonymous survey link was sent to all 18 hematologists in the leukemia division and was
open for 10 days. Nine hematologists (50%) responded to the survey with 100%
completion of both questions. The average time spent completing the survey was five
minutes.
Content analysis of each question began with examination of each response and
assigning various tags using the tag tool in the SurveyMonkey student package.
Thematic analysis of the tags was completed with the assistance of a Doctor of
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Philosophy (PhD) NP and themes were identified. The tags/themes were then
independently reviewed by a DNP, a master’s prepared supportive care NP, two
supportive care physicians and one hematologist. The word cloud feature, which finds
common words that are used most often in the responses, was not useful in analyzing the
content.
Question #1
The purpose of the first question was to explore the hematologists’ definitions of
and key components of GOC conversations in one or two sentences.
Twenty-two tags were created from the 9 answers and assigned appropriately to
each response (Figure 12). The number of tags assigned to each question ranged from 5
to 9, the average being 6.3.
Figure 12
Tags Assigned to Question #1 Responses

Question 1 Tags
10
9
8
7
6
5
4
3
2
1
0

9

9

5
4

4

3
2

2

2
1

1

1

1

1

2
1
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Clinical situation and communication were the two dominating themes and
present in 100% of the responses, in some form. From these, six sub-themes emerged
with further thematic analysis, each containing 2-5 of the tagged categories (see Table 2).
Table 2
Clinical Situation and Communication Sub-Themes
Sub-Theme
Current
Condition/Information

Diagnosis
Prognosis
Current/previous treatment
Treatment Response
Options/Treatment/Strategies Plan for tx
Hope for tx
Clinical trial
(end) Hospice, DNR, CC
Side effects/Complications
Outcomes
Expected outcomes-PT
Expected outcomes-MD
Best/Worst case scenario
Understanding
Mutual Understanding
Patient Understanding
Decision Making
Joint Decisions
Alignment
Patient Values/Wishes
Concept
Clarifying what GOC means to the patient.
Dynamic
Not hospice, DNR, Comfort Car

Question #2
The purpose of the second question was to gain insight into the hematologists’
perceived barriers to having/documenting GOC conversations in the inpatient setting.
Barriers may include thoughts surrounding prognostication, culture, effect on hope,
comfort level with conversations, time constraints, or pressure to change practice.
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Seventeen tags were created and appropriately assigned to each of the nine
responses. The number of tags for each response ranged from 2 to 5, the average being
2.8 (see Figure 13). Five themes emerged, each containing 2 to 5 tagged sub-themes (see
Table 3).
Figure 13
Tags Assigned to Question #2 Responses

Question 2 Tags
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1

1

1

Table 3
Themes and Sub-Themes
Theme

Sub-Theme

Timing/Location

Emergency/unexpected change in patient condition
Timing/patient condition; goal is cure
Location- Clinic setting is best.
Difficult to coordinate
Personal/behavioral Avoidance
Difficult/Depressing/Unpleasant
Worried about effect on hope/never give up culture.
Ownership by primary hematologist
Prognostic uncertainty
Patient
Unrealistic expectations
Never give up attitude*
Cultural issues
Discussion
Skills required.
Too much time/don’t have time
Inconsistent messages to the patient
Concept
Global misunderstanding of what GOC discussions are
Wrong association with EOL/DNR (when typical goal is cure)

Outcomes and Objectives
Short-Term Outcomes
Four short term outcomes that were evaluated were appropriately achieved with
the research questions (see Table 4).
Table 4
Short-Term Outcomes
Short-term Outcome

Met Research Question

Quantify the number of
patients who meet
GOC pathway criteria
in 2 separate months

Y

1. How many leukemia inpatients met the established
GOC pathway criteria for poor prognosis upon
admission during the months of October 2020 and
January 2021?
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Quantify appropriate
pathway initiation and
completion of MD
documentation/billing
in poor prognosis
patients.

Y

2. How many poor prognosis leukemia inpatients
admitted in October 2020 and January 2021 had
appropriate referral for GOC pathway?
3. How many poor prognosis leukemia inpatients
admitted in October 2020 and January 2021 had a
properly documented and billed GOC conversations
utilizing the approved template prior to hospital
discharge or death?

Obtain and compile the
hematologists personal
definition of a GOC
discussion
Compile the
hematologists personal
perceived barriers in
having/documenting
GOC discussions

Y

4. How do the hematologists define “GOC
conversation” in one sentence?

Y

5. What do the hematologists identify as perceived
barriers in having/documenting GOC
conversations?

Medium-term Outcomes
Study success was also evaluated against four medium-term outcomes (see Table
5).
Table 5
Medium-Term Outcomes
Medium-term Outcome

Met Method

Analyze qualitative data
for patterns and themes
specific to this set of
hematologists
Interpret and organize
findings
Share the findings with
hematologists, APPss,
and GOC task force
Submit findings for
publication.

Y

Qualitative analysis of SurveyMonkey findings.

Y

Completion of chapters 1-5 of Scholarly project

IP

Some quantitative data has been shared with the task
force. All findings will be shared at project
completion.
F
The DNP student researcher plans to submit the
findings for publication in a peer-reviewed journal
upon completion.
Y-Outcome met, IP- In progress, F- Future
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Long-term Outcomes
In the future, the study will need to be evaluated for success against 5 long-term
outcomes (see Table 6).
Table 6
Long-Term Outcomes
Long-term Outcome

Plan

Use findings to address specific concerns
and create educational interventions for
this group of physicians.

Plug data into the CFIR, which will be
used by the task force to aid in
implementation success.

Expand the GOC pathway program to the
outpatient setting.

DNP researcher will identify an outpatient
NP “owner” and invite them to join the
task force to create outpatient roll-out
plan.
Presentation of results and ongoing NP
involvement in the project, serving as a
resource and liaison between
administration and physicians.
Align with the ADCC’s recommendations
and participation in the Improving Goal
Concordant Care Initiative.

Enhance and align hematologist
understanding of the GOC pathway and
the intended outcomes of the project.
Improve Goal Concordant Care in Highrisk leukemia patients.

Summary
This study had two explicit purposes, which were appropriately achieved through
the chosen methodology. The first purpose, to evaluate participation of APPss and
physicians in the GOC pathway process, was achieved through chart review and
quantitative analysis of the discovered data. The second purpose, to elicit hematologists’
definitions of a GOC discussion and perceived barriers to having/documenting GOC
discussions, was achieved through qualitative analysis of anonymous survey data. To
provide a broader picture, instead of analyzing the data from two consecutive months, the
study utilized data from October 2020 and January 2021. The percentage of eligible
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inpatient admissions meeting the specified criteria was similar (33%, 39%) between the
two months; however, the number of appropriate referrals (23%, 15%) and
documented/billed GOC discussions (21%, 1%) was higher in October than in January.
The reasons for the decline are unknown and further research inquiry is needed to explore
the trends and causation.
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CHAPTER V
DISCUSSION
The general purpose of nursing research is to answer relevant questions and solve
problems in nursing practice (Polit & Beck, 2021). Research purposes and specific study
goals can range along a descriptive/explanatory continuum, but a fundamental distinction
separates the studies that aim to describe phenomena and those that are cause-probing
(Polit & Beck, 2021). This study had two explicit purposes, which were appropriately
achieved through this mixed-methods study.
The global, over-reaching purpose of this research was to improve EOL quality in
hematology patients by reducing the number of patients who experienced ICU admission
in the last 30 days of life. The focus of this research was to evaluate a program that was
created in response to a nation-wide request for a solution to this problem. The
theoretical framework (CFIR) and study purposes were determined by utilizing the 5
“whys” to transform a very large, complex, intimidating problem into a smaller,
manageable, less intimidating problem that could be addressed in a single study. Though
the effectiveness of this root cause analysis (RCA) tool has been questioned periodically
for assuming the existence of only linear failures (Latino, 2015), the 5 “whys” was easily
modified by the researcher (see Figure 1) to acknowledge the divergent causes of each
“why,” without directly addressing and researching the issues, all of which may be
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appropriate topics for future research. Addressing the 5th “why” in a single study
required a mixed-methods design with two purposes, each lying on opposite ends of the
descriptive/explanatory continuum. Quantifying the number of admitted patients who
met GOC pathway criteria and comparing that number to the number of referrals and
appropriately documented/billed GOC discussions effectively described the lack of
program participation amongst the providers, and qualitative exploration sought to
explain and understand why this lack of participation exists.
Relationship of Outcomes to Research
Translating Evidence, Planned Change, and Project Implementation Evaluation
Using evidence in practice is a complex process that requires more than a
practitioner’s ability to critically appraise evidence and make rational decisions. The
implementation of evidence-based practice depends on the achievement of significant and
planned change involving individuals, teams, and organizations (Rycroft-Malone &
Bucknall, 2010). Many research-proven interventions fail to translate into meaningful
change in the healthcare delivery system; some estimates indicate that up to two-thirds of
organizations’ efforts to implement change fail (Burnes, 2004).
In October 2020, only 6% of patients who met criteria for pathway initiation had a
properly documented/billed goals discussion in their electronic medical record at the time
of data collection; that number further declined to 1% in January 2021. In 2017 Keith et
al suggested utilization of a structured model to aid in rapid-cycle evaluation of practice
transformation initiatives. In 2009, Damschroder et al. made recommendations for
successful program implementation after their study found that success is more likely
when monitoring progress for unanticipated influences (barriers and facilitators) and
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progress toward implementation goals. Logically, one could infer that the inverse is true,
and that failure is more likely when the implementation plan does not monitor progress
for unanticipated influences (barriers and facilitators) and progress toward
implementation goals. The decline in program participation occurred in the absence of a
theoretically based implementation evaluation plan, which inversely supports
Damschroeder et al’s (2009) findings.
The Problem of Aversion
The phenomenon of hematologist aversion to EOL discussions and poorer EOL
quality in hematology is well documented, as is the increased discordance regarding
prognosis, treatment goals, and EOL preferences between hematologists and their
patients (Earl et al., 2008; Fletcher et al., 2016; Ho et al., 2011; Howell et al., 2011; Hui
et al., 2014; LeBlanc et al., 2015; O’Connor et al., 2014). This study found that up to
90% of inpatient admissions meeting criteria for GOC discussions via GOC pathway
lacked documentation/billing of these discussions in their electronic medical record.
While this does not prove a pattern of patient/provider misalignment regarding prognosis,
treatment, EOL preferences, or goal discordance, it does support an aversion to GOC
discussions amongst leukemia hematologists in addition to the heavily researched
aversion to EOL discussions. (Howell et al., 2011, Prod’homme et al., 2018, Ojejide et
al., 2014). This research offers a very new and small window of insight into why this
suggested pattern of discussion aversion exists despite the growing body of evidence
supporting the want, need, and absence of these crucial discussions in patients with
hematologic malignancies (Bernacki, 2015).
Misconceptions
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The concept of GOC is historically ambiguous and inconsistent between providers
(Brandt et al., 2012). In 2016, Susan Stanek sought to clarify the concept of GOC using
Norris’s method of concept clarification to create an operational definition. She reports
three key findings: 1) GOC are the established, agreed on, desired health expectations
that are appropriate, documented and communicated. 2) GOC are formulated through the
thoughtful interaction between a human being seeking medical care and the healthcare
team. 3) Patients, members of the healthcare team and the healthcare system when GOC
are established. There is no mention of EOL or death in her (Stanek, 2016) definition.
Perception and stigma remain an issue in the hematology setting.
As shown in much of the previous research on the subject, existence of a
stigmatic association of “GOC” with “EOL” (Corbett et al., 2013; Ganguli et al., 2016;
Piggott et al., 2019) is evident in this study sample. Some of the hematologists described
the conceptual barriers of themselves and their peers surrounding the GOC discussion,
while others described their barriers based on their own misconceptions (Table 7). Many
of the same barriers exist for GOC discussions in these hematologists as Prod’homme et
al (2018) described as barriers to EOL discussions, which increasingly demonstrates the
lack of separation between the two concepts.
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Table 7
Misconceptions
Type of
Barrier
Self-Aware

Example
“One barrier to GOC discussions is that both physicians and patients
typically associate them with EOL discussions.”
“Misunderstanding of the GOC discussions among many people
involved- including health care professionals and patient/families.”
“The GOC discussion has nothing to do with ‘not escalating their
medical care’ or ‘nothing to offer,’ or ‘you have a poor prognosis and
there is no or little hope’.”

Unaware

“The GOC discussions and more specific management items such as
code status/comfort care, etc. need to be de-coupled.”
“GOC discussions are sometimes difficult and depressing.”
“It is unpleasant to deliver bad news.”
“Effect on hope”
“The typical goal is cure in patients with hematologic malignancies.”
“Cultural issues, which make talking about death taboo”

Prognosis
It has been shown that hematology patients are more likely to experience ICU
admission in the last 30 days of life, which contributes to poor EOL quality, and that
earlier and better GOC discussions increase EOL quality and goal concordance between
clinicians and their patients (Mack et al., 2012; Roman et al., 2019; Starr et al., 2019;
Wright et al., 2008; Wright et al., 2010; Weeks et al., 1998; Prigerston, 1991). Through a
survey, Habib et al (2019) found that the majority of hematologists reported discussing
prognosis with their patients at diagnosis, yet even though prognosis evolves during the
disease course, one in five (20%) reported never readdressing prognosis again with their
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patient, or only doing so near death. Therefore, nearly four out of five (80%)
hematologists do not readdress prognosis throughout the disease trajectory, hence
engaging in “silent GOC discussions” that do not contain current, factual prognostic
information. The quantitative lack of documented goals discussions containing
prognostic information found in this inquiry may support this finding; however, a
prognostic qualitative theme emerged as many of the hematologists define the
components of a goals discussion and describe their barriers. The silent conversations are
more likely lack of documentation than lack of existence in this case (Table 8).
Table 8
Prognosis
Question

Example

1-Definition
and
Components

“A meeting to align patient goals with provider understanding of
prognosis.”
“To carry with the patient a conversation to educate them about…
prognosis and understand their wishes in regards to what's important
to them”
“Diagnosis, prognosis, options for treatment, clinical trials, back-up
plan.”

2-Barriers

“A careful discussion…prognosis, clinical situation and what the
patient’s objectives are given the reality of the situation.”
“It’s hard to assess impact of treatment that may impact
prognosis/outcomes of survival”
“Sometimes lack of all information needed to accurately determine
prognosis.”
“Physicians often prognosticate based on unrealistic expectations
regarding the likelihood of good outcomes in the face of recurrent
disease”
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Barriers to Goals-of-Care Discussions in Hematology
Previous research has explored barriers to EOL discussions hematology and GOC
discussions in medical oncology. To date, there is no research focused on GOC
discussions in hematology. Piggott et al. (2019) surveyed and reported barriers to GOC
discussions from the perspective of medical oncology practitioners and found that
participants perceived patient and family member factors as the most important barriers
to GOC discussions. These included family members’ difficulties accepting a poor
prognosis, lack of family agreement in the GOC, difficulty understanding the limitations
of life-sustaining treatments, lack of patients’ capacity to make GOC decisions, and
language barriers. Patient and family factors were not identified as a theme in
hematologist perceived barriers to GOC discussions. Both the 2019 study and this study
did find lack of time to be a perceived barrier to GOC discussions (Table 9).
Table 9
Lack of Time
Question

Example

1-Definition
and
Components
2-Barriers

N/A
“Time constraints, challenge of scheduling.”
“Time constraints…”
“Usually takes one hour or more.”
“Number of eligible patients might exceed the time capacity that one
would want to spend on this.”
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Observations
The evolving role of APP as influencers and crucial components in the health care
system is increasingly recognized as these professionals continue to expand and display
their knowledge (Kilpatrick et al., 2011). In this study setting, the unique professional
relationship between hematology Medical Doctor (MD) and APP creates a captive MD
audience for which the APP should utilize to affect evidence-based practice change
interventions by influencing, educating, and guiding the physician's practice when a
change from the “old ways” is necessary. In most settings, the value of the APP is
recognized by the supervising physician and is respected and appreciated (Trautmann et
al., 2015). The evolution of advanced practice into what it is today can be fully attributed
to many years of thoughtful motivation and a united vision of practicing to the highest
extent of one’s knowledge and ability (Hanson & Hamric, 2003).
Initially, this study aimed to further explore and explain hematologist’s barriers to
having/documenting GOC discussions. The quantitative inquiry was designed to describe
physician compliance in GOC pathway completion, however, during data collection, the
role of the APP in physician non-compliance became apparent. While physician barriers
must be explored, it became increasingly evident that APP barriers to implementation
initiatives must also be explored in future research. To compare the number of poor
prognosis patients identified to the number who had properly documented/billed goals
discussions would create an unfair disadvantage to the hematologists. The number of
pathway initiations by the APP/GOC meeting requests needed to be compared to the
number of documented/billed discussions to more clearly understand the issues at hand.
Furthermore, the lack of APP buy-in in the setting of unsuccessful practice-change
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initiatives further supports the power of APP presence and leadership in the successful
implementation of initiatives.
Evaluation of Theoretical Framework
The CFIR was chosen as a theoretical framework to evaluate the progress of
program implementation of the GOC pathway an independent dedicated cancer center in
Southern California. The framework was chosen because of the apparent generalizability
of the model, which was constructed based on analysis of 19 implementation research
models (Damschroder et al., 2009). Since the 2009 publication, the Consolidated
Framework for Advancing Implementation Science has been cited in numerous
publications, all of which support the successful utilization of the framework for
implementing hospital-based practice change. A 2015 study (Breimaier et al.) found the
CFIR a valuable and helpful framework for: 1) Assessment of the baseline process and
final state of the implementation process and influential factors. 2) The content analysis
of qualitative data collected throughout the implementation process. 3) Explaining the
main findings. Also, in 2015, the generic implementation framework was published, and
was based on the 5 domains of the CFIR (Moullin et al., 2015). In Keith, Crosson et al’s
(2017) study using the CFIR across 21 primary care practices participating in the
comprehensive primary care initiative, results showed that utilizing the CFIR to guide
data collection, coding, analysis, and reporting of findings supported a systematic,
comprehensive, and timely understanding of barriers and facilitators to practice
transformation. Their approach to using the CFIR produced actionable findings for
improving implementation effectiveness during the initiative and for identifying
improvements to implementation strategies for future practice transformation efforts.
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Throughout this research process, many theoretical frameworks were seen in the
literature, but, because of the generalizability and adaptability of the CFIR to almost any
setting, it is still thought to be the most appropriate model for this project.
Evaluation of Logic Model
The logic model chosen (Figure 3) was appropriate and clearly stated the
objectives, resources, activities, and outputs. The objectives were related to the short,
medium, and long-term outcomes and were achieved through the activities and outputs.
Cited resources plus additional resources obtained throughout the process were also
utilized to reach the objectives. The simplicity of the logic model made it the most
appropriate for this project as it was easy to read and gave a clear roadmap of the project
aims.
Limitations
The primary limitation of this study lies within the research topic itself, GOC.
There is an overall lack of interest in GOC, which was noted in the mere 50% survey
response rate. The novice level of experience possessed by the principal researcher may
also be a limitation. The sample size may be considered a limitation as well as the 50%
response rate to the survey. Several known limitations were recognized as assumptions
early in the research process. It was an assumption that each hematologist would answer
the survey only once and do so truthfully. However, the anonymous survey link sent via
e-mail was not designed to limit the response to one per person, but instead it was
designed to promote easy access and maintain anonymity. The quantitative chart review
method presented limitations due to human error and processing since each chart was
personally reviewed by the researcher, and criteria for the pathway was determined by the
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researcher’s interpretation of the information in the patient’s electronic medical record.
Also, the study was completed during the COVID-19 pandemic and visitors/family
members were not allowed in the facility, therefore, GOC meetings had to take place via
Zoom or other remote communication method. The anxiety of learning to live with
COVID-19 fears and the changes it brought upon may have caused additional aversion to
GOC discussions in hematologists.
Instrument Limitations
Due to the anonymous survey study design, the responses lacked the advantage of
verbal conversation and back-and-forth interaction that takes place with personal
interview methods of qualitative discovery. It was impossible to ask for clarification of
thoughts or ideas, the interpretation was determined by the health care professionals who
examined the data. Prod’homme et al.’s (2018) study used personal interview of ten
hematologists to explore the barriers to EOL discussions when potentially fatal
hematological malignancies recur, and this study sought to similarly describe barriers to
GOC discussions in patients with relapsed high-risk leukemia. The anonymous survey
instrument was chosen because it was thought to be the most likely method to
successfully collect the candid opinions/thoughts of at least fifteen hematologists, but the
low response rate collected the thoughts of only nine hematologists. Also, the instrument
demanded interest and effort on the part of the respondent, whereas personal interview
could be considered less effort for the hematologist. The hematologists who already
possess some level of interest in improving GOC discussions at the facility are likely the
ones who took the time to thoughtfully respond to the survey. It is likely that the
hematologists who possess the strongest barriers to GOC discussions also possess a
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strong disinterest in of the subject that would deter them from participating in the survey.
Also, due to the anonymous survey design, it was an assumption that each hematologist
would truthfully respond to the survey questions one time, and that the survey link would
not be shared with anyone else who may access and complete the survey. The selfreported nature of the survey also presented an opening for the hematologists to distort
their responses or behavior to present themselves in the best light, based on unawareness
of self-behavior. The intent was to use open-ended, broad questions that did not lead the
respondent in their response; however, the inclusion of examples in question #2 may have
led or guided response to the survey and caused data collection biases.
Sample Limitations
The original intended sample size of 20 hematologists was reduced to 18 due to
one hematologist retiring and one leaving the practice. Neither physician had been
replaced when the survey was opened. The time, or perceived burden of time, required to
complete a survey could have played a role in the choice not to complete the survey.
This study as well as any study that qualitatively examines hematologists and GOC will
likely contain a bias towards those who have examined the existing data, recognize the
problem as a problem, see the need for further research of the problem, and have already
put forth effort to change and improve the way they practice. The providers who are
resistant to change to their practice habits may not see a need to research or contribute to
research that studies the topic.
Design Limitations
The original intended sampling method was an identical mixed method sampling
design that included the same people in both strands of the study. It was only during
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deep contemplation of the study limitations that the researcher recognized that the
quantitative and qualitative data were not obtained using this type of sampling method.
The quantitative data was obtained by evaluating all hematology admissions excluding
BMT admissions for pathway criteria. Therefore, the quantitative results reported are
from all hematology admissions, including the patients who were admitted to the
lymphoma and lymphoma/myeloma teams. Only one of the properly documented/billed
GOC discussions during October 2020 and January 2021 was authored by a leukemia
hematologist, the others were completed by physicians from the lymphoma, myeloma,
and supportive care teams. Therefore, the scope of the problem specifically in leukemia
hematologists is not accurately described. While this does create a bias in the
quantitative data, the effect on the qualitative study purpose is thought to be minimal.
The qualitative inquiry is new research and considered to be the most useful component
in promoting program success. The study findings will be used to address the
hematologists barriers by developing tailored implementation interventions guided by
their educational needs. Quantitative data is needed to formally evaluate all programs in
the healthcare setting and was therefore necessary to be collected; however, in this case
the data was used to more accurately describe a global problem that already exists in
healthcare- implementation failure.
Implications for Future Projects and/or Research
Throughout the course of this scholarly inquiry, many system issues were
uncovered that could benefit from further exploration. The quantitative data shows lack
of implementation success within the lymphoma and lymphoma/myeloma teams and
future research endeavors should explore the barriers to GOC discussions in lymphoma

74

and myeloma specialty hematologists. Also, the contributory role of the APP to program
implementation success or failure should be researched so that implementation endeavors
are collaborative and successful. In this case, the APP’s role evolved into one of the most
influential factors of program success. The APP is responsible for properly initiating the
GOC pathway with a specific social work order in patients who meet the pathway
criteria, yet 75% of the time there was a failure to do so; therefore, the APP barriers need
to be researched in the future. Another area of needed research involves the lack of
integration of supportive and palliative care into hematology to determine where in the
disease trajectory these services are best utilized and how the APP can promote
collaboration within the two specialties. Patients with hematologic malignancies rarely
receive specialist palliative or hospice care and studies prospectively evaluating potential
effects of integrated palliative care in these patients are rare (Oechsle, 2018).
Implications for Practice
This study was an important first step towards understanding the barriers that
hematologists possess surrounding GOC discussions. As of September 2020, the success
of the GOC pathway changed from desired to required when the ADCC implemented the
IGCC initiative. The ADCC is made up of America’s leading cancer centers and
prioritizes protecting innovation, improving efficiencies, preserving quality-focused
health policies, and measuring and setting standards for cancer care; being a part of the
alliance’s pooled resources offers great benefit to each member institution. The survival
rates are 16% higher than community hospital centers and 8% better than academic
centers after five years (ADCC, 2019). As part of the ADCC, institutions are expected to
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participate in the initiative to improve quality and maintain the integrity of the
organization’s positive reputation nation-wide.
Quality-focused health policy continues to evolve based on the newest evidencebased facts. But institutional culture and practice change is difficult to achieve. The
leaders, innovators, early adopters, and early majority must continue to develop education
and programs based on the specific needs of the laggards and late majority. APPs should
exercise their influence in the healthcare social system as opinion leaders, change agents,
and champions to better diffuse innovation. The doctorly prepared APP possesses the
ability to routinely incorporate and utilize theory, such as the diffusion of innovation
theory (Rogers, 1962) in planning and implementing practice-changing quality initiatives
and evaluating the success of these programs.
Conclusion
This study aimed to describe and explore implementation of an institutional GOC
pathway program, and hematologists barriers to having/documenting GOC discussions in
relapsed high-risk leukemia patients. The study confirmed suspicions that program
participation was low and needed evaluated for improvement in implementation. The
almost absent number of properly documented GOC discussions warranted exploration of
their barriers and offers valuable insight into the hematologist’s aversion to GOC
discussions. This information will be used for program evaluation with the CFIR, then
incorporated into institutional efforts to achieve each of the four core components
described in the IGCC initiative implementation planning guide. The initiative was
created by the ADCC to address system gaps and establish new expectations for when
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and how GOC conversations occur, and the implementation will occur over a three-year
period, between September 2020 and September 2023.
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APPENDIX

APPENDICES
Appendix A: Patient Support Screen
Hello,
Many patients tell us that being in the ICU can feel overwhelming, especially if you’re
unsure about the next steps in your care and treatment. As part of your care, we meet with
you and your family so that you can get up-to-date information about your condition and
discuss any questions or concerns you have about your treatment.
With any serious illness, it helps us to know what your values and goals are so that we
can honor what’s important to you. The information you share will enable us to know
your wishes and best work together as a team.

1. In case you are ever not able to speak for yourself, who do you want to make
medical decisions for you?
Type in name
2. How is this person related to you?
□

Spouse

□

Partner

□

Parent

□

Child

□

Sibling

□

Friend

□

Other, explain

3. Which statement is closest to your understanding of your present medical
situation?
□ Cure is very likely and is in the range of 76% to 100% for me
□ Cure is likely and is in the range of 51% to 75% for me
□ Cure is possible but not likely and is in the range of 26% -50% for me
□ Cure is not at all likely and is in the range of 0-25% for me
The goal of treatment is to control the disease for as long as possible
□ Cure is not at all likely and s in the range of 0-25% for me
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The goal of treatment is to focus on comfort, time with family and quality of
life
4. What is most important to you if your medical condition gets worse?
□

To live for as long as possible regardless of my medical condition

□ Continue treatment for a period of time but stop if there is no chance for a
meaningful recovery
□

Continue treatment focused on quality of life and comfort only

5. Right now, what is the most concerning to you?
□

Being able to communicate

□

Pain

□

Not getting better

□

How my family is coping

6. What abilities are so critical to your life that you can’t imagine living without
them?
Check all that apply
□

Interacting with family and friends in a meaningful way

□

Performing daily living activities independently

□

Making my own decisions

□

Engaging in activities that bring me joy

□

Nothing is so critical that I cannot imagine living without

7. Have you shared your health care wishes and goals with your family?
□ Yes
□ No
8. Has the medical team explained your treatment plan in a way you can
understand?
□ Yes
□ No
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9. At this time, do you feel you are getting a consistent message from your
doctors about your treatment plan?
□ Yes
□ No
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Appendix B: Cover Letter
Hello again!
I am very proud to announce that I am pursuing higher education and have chosen to
incorporate my role in improving goal concordant care at COH into my scholarly
research project. Chart review of patients admitted to the Hematology/Hem transplant
readmit service lines (excluding BMT) for the months of October 2020 and January 2021,
indicated that ~30% of our inpatient admissions meet the criteria for consideration of
inpatient GOC discussion.
I would like to understand your perceived barriers to having/documenting GOC
discussions. Please be candid, this is an anonymous survey and participation is entirely
voluntary. Your answers will be compiled, analyzed, examined for trends, and included
in my scholarly project final writing, which I plan to submit for publication once
completed. The findings will also be shared with you as we continue to implement the
ADCC’s Improving Goal Concordant Care initiative at City of Hope! Physicians, please
click the link below to complete my short survey. THANK YOU SO MUCH FOR
YOUR SUPPORT!
https://www.surveymonkey.com/r/LACYJO-DNP-GOC
Consent is implied by voluntary completion of the survey. Please see the attached
complete informed consent document.
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Appendix C: SurveyMonkey Questionnaire
1. In one sentence, please give your definition of a GOC conversation.
2. Please describe your perceived barriers to having/documenting GOC
conversations. Examples may include thoughts surrounding prognostication,
culture, effect on hope, comfort level with conversations, time constraints, or
pressure to change the way you practice.
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